论文部分内容阅读
急性心肌梗死(AMI)早期并发轻中度心力衰竭者应用血管紧张转换酶抑制剂(ACE—I)疗效已肯定;但因左室(LV)扩大和慢性心衰(CHF)是心肌梗死(MI)后病人预测死亡的重要指标,且LV扩大在CHF的发展中起重要作用.为探讨ACE—I长期连续应用对AMI并发轻中度心衰者LV扩大和CHF的发生率及病死率的影响,本文采用开搏通(Capoten.中美上海施贵全公司生产)以随机对照分组方式跟踪2年.观察其疗效.现报告如下.1 材料和方法11 病例选择 1989年元月～1992年元月我院冠心病监护病房的AMI(符合WHO诊断标准).在发病10天内并发心衰(KilliP分级Ⅰ级和Ⅱ级)者,除伴有肾功能不全和持续性低血压(收缩压<12kPa持续2小时以上)及(或)发病前长期使用大量利尿剂的患者37
The efficacy of angiotensin converting enzyme inhibitor (ACE-I) has been validated in patients with early-stage acute myocardial infarction (AMI) complicated with mild-to-moderate heart failure. However, due to increased left ventricular (LV) and chronic heart failure ) Is an important index of prognosis of patients, and the enlargement of LV plays an important role in the development of CHF.To investigate the effects of long-term continuous application of ACE-I on LV enlargement and the incidence of CHF and mortality in AMI patients with mild to moderate heart failure , In this paper, Captopin (Capoten. Sino-US Shanghai Shi Gui company production) randomized controlled grouping followed 2 years observation of its efficacy are reported as follows.1 Materials and methods 11 case selection January 1989 January to January 1992 I AMI of hospital coronary care unit (in line with WHO diagnostic criteria) .At 10 days after the onset of heart failure (KilliP grade Ⅰ and Ⅱ), with renal insufficiency and persistent hypotension (systolic blood pressure <12kPa for 2 Hour or more) and / or long-term use of large amounts of diuretics before onset 37